Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Aug 2;22(23):5682–5687. doi: 10.1158/1078-0432.CCR-16-1031

Figure 5.

Figure 5

Representative CAT scans demonstrating activity (ie, partial response) of nivolumab in Patient #2 (ie, MSH6-hyper-mutated). Left panel: Pretreatment image with baseline measurement of a representative metastatic tumor deposit (ie, right common iliac mass invading the psoas muscle and obstructing the right ureter). Middle panel: Regression of the metastatic tumor deposit described above three months after treatment initiation. Right panel: Continue regression (Right Panel) of the metastatic tumor deposit nine months after treatment initiation with nivolumab.